Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT01107665 Phase II Paclitaxel + Pazopanib Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma Completed
NCT01693068 Phase II Dacarbazine Pimasertib Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma Completed
NCT02203604 Phase II Aldesleukin + Ipilimumab High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Completed
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02535078 Phase Ib/II Durvalumab Tebentafusp Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Recruiting
NCT02581930 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma Active, not recruiting
NCT02680184 Phase I Pembrolizumab + QbG10 Clinical Study of CMP-001 in Combination With Pembrolizumab Active, not recruiting
NCT02731729 Phase II Ipilimumab Nivolumab Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy Completed
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Active, not recruiting
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Active, not recruiting
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Active, not recruiting
NCT03084640 Phase Ib/II Pembrolizumab + QbG10 Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma Recruiting
NCT03089606 Phase II Pembrolizumab Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker Active, not recruiting
NCT03405155 Phase II Nivolumab Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery Active, not recruiting
NCT03551626 Phase III Dabrafenib + Trametinib Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) Active, not recruiting
NCT03553836 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Recruiting
NCT03618641 Phase II Nivolumab + QbG10 CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease Recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Recruiting
NCT03864042 Phase I Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Recruiting
NCT03875079 Phase I Pembrolizumab + RO6874281 A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma Recruiting
NCT03897881 Phase II mRNA-4157 + Pembrolizumab Pembrolizumab An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) Recruiting
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting
NCT03972046 Phase II Dabrafenib + Talimogene laherparepvec + Trametinib Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Withdrawn
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Not yet recruiting
NCT04007588 Phase II Ipilimumab + Nivolumab Nivolumab BMS-986205 + Nivolumab A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Withdrawn
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Recruiting
NCT04042506 Phase II Nivolumab SBRT as a Vaccination for Metastatic Melanoma Recruiting
NCT04099251 Phase III Nivolumab Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) Recruiting
NCT04135352 Phase I Pembrolizumab + V938 A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) Recruiting
NCT04136834 Phase I Pegtomarginase A Phase I Open-label Study for Subjects With Advanced Malignancies (PT01) Not yet recruiting
NCT04139902 Phase II Dostarlimab + TSR-022 Dostarlimab PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) Recruiting
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting
NCT04356729 Phase II Atezolizumab + Bevacizumab A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Not yet recruiting
NCT04375527 Phase II Binimetinib + Nivolumab Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Not yet recruiting
NCT04401995 Phase II Nivolumab Nivolumab + QbG10 Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab Not yet recruiting
NCT04493203 Phase II Axitinib + Nivolumab Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Not yet recruiting
NCT04495010 Phase II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) Not yet recruiting